COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #51 of 230
6/3 Post Exposure Prophylaxis study (treated after exposure to the virus)
Boulware et al., NEJM, June 3 2020, doi:10.1056/NEJMoa2016638 (Peer Reviewed)
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Source   PDF   Share   Tweet
COVID-19 cases are reduced by [49%, 29%, 16%] respectively when taken within ~[70, 94, 118] hours of exposure (including shipping delay). The treatment delay-response relationship is significant at p=0.002. PEP delayed treatment RCT.
For more detailed analysis, see [1].
6 independent analyses of the data in this study confirm efficacy: [2, 3, 4, 5, 6, 7, 8].

Boulware et al., 6/3/2020, Randomized Controlled Trial, USA, North America, peer-reviewed, 24 authors.
risk of COVID-19 case, 17.0% lower, RR 0.83, p = 0.35, treatment 49 of 414 (11.8%), control 58 of 407 (14.3%).
risk of COVID-19 case, 25.1% lower, RR 0.75, p = 0.22, treatment 32 of 414 (7.7%), control 42 of 407 (10.3%), probable COVID-19 cases.
Details of all 230 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit